Ask AI
ProCE Banner Activity

Beyond Efficacy: Equitable Access Is the Next HIV Prevention Breakthrough

Clinical Thought

AIDS 2026 made one point impossible to ignore: In HIV prevention, science is no longer the main limitation. The most practice-changing data presented at this meeting were not simply another demonstration that long-acting PrEP works. Investigators showed that long-acting PrEP can be accepted, sustained, and delivered across very different populations and settings. Read on to learn how I think our health systems can and should make that choice available.

Released: August 20, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported through independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Partners

International AIDS Society

ProCE Banner

Target Audience

This program is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Integrate the latest scientific findings to develop and optimize effective HIV prevention interventions

Financial Disclosures

Primary Author

Claudia P. Cortes, MD: consultant/advisor/speaker: Merck, Pfizer, ViiV.